Bayer HealthCare Pharmaceuticals announced that its experimental, genetically engineered...
Federal health experts are taking a second look this week at the heart safety of pain...
Bayer HealthCare to Invest in Manufacturing Operations as Next Step in Recent Animal Health Business AcquisitionJanuary 20, 2014 2:57 pm | News | Comments
Bayer HealthCare LLC has announced that the company will be improving efficiency and investing...
Regeneron Pharmaceuticals and Bayer HealthCare today announced an agreement to jointly develop an innovative antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a potential combination therapy with EYLEA (aflibercept) for the treatment of wet age-related macular degeneration (wet AMD).
Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based company to nearly $2.9 billion. The two firms said Thursday drug and chemical company Bayer will make a cash offer of 362 kroner ($59.24) per Algeta share.
Moberg Pharma AB has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources.
Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion. Algeta said in a statement Tuesday that the offer is for 336 kroner ($55.11) per share; the company has nearly 44 million shares.
The FDA has expanded approval of a Bayer drug to treat patients with thyroid cancer. Bayer's pill Nexavar is already approved to treat kidney cancer and liver cancer that cannot be surgically removed. Now the FDA has approved the drug to treat cancerous growth of the thyroid gland, which is located in the neck.
Drug and materials company Bayer AG says net profit rose 42 percent as sales increased for its new drugs aimed at preventing blood clots and treating the eye disease macular degeneration, while one-time expenses dropped. Net profit reached $1.01 billion.
Bayer HealthCare said Tuesday its drug Adempas has been approved as a treatment for two types of pulmonary hypertension, or high blood pressure in the arteries of the lungs. Bayer said it is already launching the drug, and called Adempas the first drug approved by the Food and Drug Administration...
Olivier Brandicourt has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013. Since March 2013, Professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member.
The pharmaceutical giant Bayer AG confirmed Friday that it is being investigated in China for possible unfair competition, making it the latest foreign drug maker to come under scrutiny in the country. The Germany-based company said it is cooperating with Chinese authorities in the investigation...
Onyx Pharmaceuticals and Bayer have announced that European Union regulators approved their pill Stivarga as a treatment for colorectal cancer. The companies said Stivarga was approved for the treatment of metastasized colorectal cancer in adults. In the U.S. Stivarga is approved as a treatment for...
The FDA granted priority review designation to a marketing application seeking approval of Bayer and Onyx Pharmaceuticals' Nexavar (sorafenib) for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, the companies said Tuesday.
Regeneron Pharmaceuticals and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA@ (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity (BCVA) from baseline.
Bayer AG says net profit rose 75 percent in the second quarter thanks to lower one-time charges and strong sales of new products including anti-clotting drug Xarelto and cancer drug Stivarga. But falling earnings at its high-tech materials division led the the company to say it would be harder to achieve its earnings goals for the year.
Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application (sNDA) to the FDA and an application for marketing authorization to the EMA for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.
Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets.
Actavis, Inc. today confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Drospirenone/Ethinyl Estradiol/Levomefolate Calcium Tablets And Levomefolate Calcium Tablets. Actavis' ANDA product is a generic version of Bayer's Safyral, which is approved to prevent pregnancy in women who elect to use an oral contraceptive, and to provide a daily dose of folate supplementation.
Bayer AG has acquired a majority stake in birth control maker Conceptus Inc. and expects its $1.1 billion purchase of the California company to be completed soon. Bayer said Wednesday that more than 96 percent of the company's outstanding shares were validly tendered and not withdrawn during an offer period that expired Tuesday.
A group of Jefferies & Co. analysts said yesterday that drug companies are putting more emphasis on restructuring and spinning off parts of their business, and that those moves will be a critical factor in stock performance in 2013 and 2014.
Bayer AG has received antitrust clearance from the Federal Trade Commission for its approximately $1.1 billion acquisition of Conceptus. Bayer announced the deal last month, saying that it would help to expand the kinds of birth control it offers.
The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones. The FDA said Wednesday it approved the drug, Xofigo from Bayer Pharmaceuticals, for men whose cancer has grown into bone tumors even after receiving medication or surgery to lower testosterone.
Berlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
Bayer AG says it has agreed to buy California-based Conceptus for around $1.1 billion to expand the kinds of birth control it offers. Bayer said Monday it would launch a public offer to pay $31.00 per share for all the stock in Conceptus, Inc., which is based in Mountain View.
German chemical and pharmaceutical company Bayer AG said Thursday that its net profit rose 11.5 percent in the first quarter as new drugs, led by blood thinner Xarelto, boosted sales. The company also saw stronger demand in emerging markets — which helped overcome weaker business in Europe, which...
Bayer HealthCare announced today that the NDA for its oral investigational compound riociguat has been accepted for filing and granted priority review by the FDA for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH).
Bayer HealthCare and Onyx Pharmaceuticals, Inc. announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Stivarga (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC).
- Page 1